查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1985727

食道癌市場：治療方法、癌症類型、分期和最終用戶分類的全球市場預測，2026-2032 年

Esophageal Cancer Market by Treatment Type, Cancer Type, Disease Stage, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，食道癌市場價值將達到 174.5 億美元，到 2026 年將成長至 189.4 億美元，到 2032 年將達到 310.1 億美元，複合年成長率為 8.56%。

主要市場統計數據
基準年 2025 174.5億美元
預計年份：2026年 189.4億美元
預測年份：2032年 310.1億美元
複合年成長率 (%) 8.56%

簡要介紹現代食道癌治療的臨床複雜性、診斷的突破性進展以及醫療保健服務的挑戰。

食道癌在各種醫療機構中持續帶來複雜的臨床和操作挑戰。近年來，診斷技術的進步、對分子亞型更深入的了解以及全身性治療的快速發展，徹底改變了臨床診療路徑。同時，內視鏡技術和微創手術的進步也改變了根治性治療和安寧療護之間的平衡，因此需要多學科協作和發展最新的通訊協定。

分子診斷、免疫腫瘤學和不斷變化的監管期望的進步如何共同作用，改變食道癌的臨床實踐和治療方式？

由於科學、技術和監管領域各方力量的匯聚，食道癌的治療格局正在發生變革性變化。分子譜分析和新一代定序技術正在重塑診斷流程，使臨床醫生能夠在基因組層級區分腺癌和鱗狀細胞癌，並識別HER2和EGFR突變等治療標靶。這些進展正在加速標靶治療治療和聯合治療的引入，同時，基於生物標記的分層，免疫療法也不斷擴展其適應症。

評估 2025 年關稅變化對腫瘤供應鏈、採購實踐以及診斷和治療獲取的營運和策略影響。

2025年實施的關稅調整和貿易政策變化正對癌症治療和診斷設備的供應鏈產生實際影響。部分進口商品關稅的提高推高了某些醫療設備和特殊試劑的採購成本，迫使醫院和診所重新評估其供應商合約和庫存策略。在某些情況下，這些壓力正在加速供應商多元化，並促使企業更加關注區域製造夥伴關係，以降低跨境關稅波動帶來的風險。

將醫療保健服務環境、腫瘤組織學類型、疾病階段和多層次治療方法連結起來的綜合細分洞察，能夠制定個人化的臨床和商業策略。

細分分析揭示了醫療服務提供地點、腫瘤生物學特徵、分期分佈和治療方法的細微差異，這些差異直接影響臨床路徑和服務設計。以門診手術中心、醫院和專科診所等終端用戶為例，手術數量、手術全期容量和多學科協作需求等方面的差異會影響患者處理能力和資源分配。門診機構優先考慮效率和短期住院管理，醫院提供全面的圍手術全期護理和複雜病例管理，而專科診所通常專注於高度專業化的門診治療和隨訪。

美洲、歐洲、中東和非洲以及亞太地區的區域體系動態如何影響食道癌的取得、診斷能力和治療方法？

區域趨勢塑造了臨床實踐模式、監管時間表和准入管道，並顯著影響診斷和治療方法的採用。在美洲，儘管有提供先進醫療服務的集中中心，但各地區的資源可近性差異巨大。一些都市區提供尖端治療，而偏遠地區則優先考慮高效的醫療服務模式和分散的後續追蹤。該地區的政策和報銷制度通常有利於臨床有效治療方法的快速推廣，但醫療資源取得的差距仍然是一個主要問題。

醫藥創新者、診斷公司和醫療設備製造商之間的競爭與合作動態塑造了食道癌治療和診斷生態系統。

食道癌領域的競爭格局涵蓋了成熟的製藥公司、新興的生物技術公司、診斷平台提供者和專業醫療設備製造商。製藥公司致力於研發結合標靶治療和免疫療法的聯合治療，並利用生物標記最佳化適應症，以識別最有可能獲益的患者。診斷公司投資研發能夠可靠地從檢體和液態生物檢體檢體中檢測HER2、EGFR和其他具有治療意義的突變的檢測方法，而醫療設備製造商則專注於開發可擴展的內視鏡和外科手術技術，以降低併發症發生率並支持門診治療模式。

為臨床、商業和價值鏈領導者提供實用策略建議，以促進食道癌治療的公平獲取和最佳化治療價值。

產業領導者應優先投資於彌合診斷能力缺口和支持基於生物標記的治療管道。加強與病理網路的合作，並投資於可擴展的分子檢測基礎設施，可以縮短治療啟動時間，並改善標靶治療治療和免疫療法方案的患者選擇。製造商和支付方還應在風險分擔和以金額為準的合約模式方面展開合作，將已證實的治療結果與報銷掛鉤。這將擴大高成本治療的可近性，同時促進有意義的真實世界數據（REW）的收集。

為了支持策略決策，我們採用了嚴謹的混合方法研究途徑，結合了專家訪談、臨床證據整合和營運情境分析。

本研究整合了跨學科證據庫，包括同行評審的臨床文獻、監管公告、最新臨床指南以及對臨床醫生、診斷專家和供應鏈專家的訪談。主要研究包括結構化的專家諮詢，探討治療順序、診斷效用和採購趨勢；次要研究則整合了已發表的臨床試驗結果、監管措施和技術評估，為新興趨勢提供背景資訊。

簡潔扼要的結論強調，將診斷和治療創新與系統韌性結合，對於改善食道癌治療效果至關重要。

總之，食道癌的治療正處於轉折點，診斷準確性、治療創新和系統層面的適應能力將決定臨床進展能否大規模改善患者預後。分子分型以及標靶治療治療和免疫療法的拓展為個人化治療提供了切實的機會，但要充分發揮這些潛力，需要加強對診斷基礎設施、多學科診療協調和供應鏈韌性的投入。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 食道癌市場：依治療方法

  • 化療
    • 輔助性治療
    • 術前治療
    • 安寧療護
  • 免疫療法
    • 癌症疫苗
    • 查核點抑制劑
  • 放射線治療
  • 外科手術
  • 分子標靶治療
    • EGFR抑制劑
    • HER2抑制劑
    • VEGF抑制劑

第9章 食道癌市場：依癌症類型分類

  • 腺癌
  • 鱗狀細胞癌

第10章 食道癌市場：依分期分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第11章 食道癌市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第12章 食道癌市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 食道癌市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 食道癌市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國食道癌市場

第16章：中國食道癌市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Aurobindo Pharma Limited
  • Bausch Health Companies Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Hikma Pharmaceuticals PLC
  • Jiangsu Hengrui Medicine Co., Ltd
  • Johnson & Johnson Private Limited
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-757B1C9CB069

The Esophageal Cancer Market was valued at USD 17.45 billion in 2025 and is projected to grow to USD 18.94 billion in 2026, with a CAGR of 8.56%, reaching USD 31.01 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 17.45 billion
Estimated Year [2026] USD 18.94 billion
Forecast Year [2032] USD 31.01 billion
CAGR (%) 8.56%

A succinct introduction to the clinical complexities, diagnostic breakthroughs, and care delivery pressures defining contemporary esophageal cancer practice

Esophageal cancer continues to present complex clinical and operational challenges across diverse healthcare settings. Advances in diagnostics, a deeper understanding of molecular subtypes, and the rapid evolution of systemic therapies have all reshaped clinical pathways in recent years. Simultaneously, improvements in endoscopic techniques and minimally invasive surgery have altered the balance between curative intent and palliative care, requiring multidisciplinary coordination and updated care protocols.

Clinicians and policy makers face competing priorities: integrating precision diagnostics into routine workflows, improving early detection to shift stage distribution toward curable disease, and ensuring that novel systemic agents reach appropriate patient populations in an equitable manner. These imperatives are set against a backdrop of shifting payer dynamics, supply chain pressures, and regulatory emphasis on real-world evidence. Consequently, stakeholders must align clinical innovation with pragmatic delivery models to translate therapeutic progress into improved population-level outcomes.

How molecular diagnostics, immuno-oncology advances, and evolving regulatory expectations are jointly transforming clinical practice and care delivery in esophageal cancer

The landscape of esophageal cancer is undergoing transformative shifts driven by converging scientific, technological, and regulatory forces. Molecular profiling and next-generation sequencing are redefining diagnostic workflows, enabling clinicians to distinguish between adenocarcinoma and squamous cell carcinoma at a genomic level and to identify actionable targets such as HER2 and EGFR alterations. These advances have accelerated the adoption of targeted therapies and combination regimens, while immunotherapy continues to expand indications based on biomarker stratification.

Concurrently, improvements in diagnostic modalities, including enhanced endoscopic imaging and the incremental validation of circulating tumor DNA assays, are increasing the feasibility of earlier detection and disease monitoring. Surgical practice is evolving too, with minimally invasive esophagectomy and enhanced recovery protocols reducing perioperative morbidity. Regulatory pathways have adapted to accommodate accelerated approvals and bespoke label expansions, which, in turn, prompt clinicians, payers, and manufacturers to rethink evidence generation and post-approval data collection. Taken together, these shifts are creating new opportunities for personalized care but also introducing complexity around access, reimbursement, and longitudinal outcome measurement.

Assessing the operational and strategic consequences of 2025 tariff changes on oncology supply chains, procurement practices, and access to diagnostics and therapeutics

Tariff adjustments and trade policy changes implemented in 2025 have had a tangible impact on the supply chains that support oncology therapeutics and diagnostic devices. Increased duties on selected imports have raised procurement costs for some medical devices and specialty reagents, prompting hospitals and clinics to reassess vendor contracts and inventory strategies. These pressures have, in some cases, accelerated the diversification of supplier bases and stimulated interest in regional manufacturing partnerships to mitigate exposure to cross-border tariff volatility.

Pharmaceutical supply chains have responded by optimizing distribution networks and by engaging in strategic sourcing to lessen the per-unit impact of tariffs on high-cost therapies. Payers and health systems have increased scrutiny of procurement choices, seeking to preserve access while containing incremental operational expenses. In parallel, manufacturers have revisited pricing and contracting approaches, exploring value-based agreements and localized packaging or component sourcing where feasible. Collectively, these adjustments underscore the importance of adaptive procurement policies and resilient supply chain planning to ensure continuity of care for patients receiving complex cancer therapies.

Integrative segmentation insights linking care settings, tumor histology, disease stage, and layered treatment modalities to inform tailored clinical and commercial strategies

Segmentation analysis reveals nuanced differences across care delivery locations, tumor biology, stage distribution, and treatment modalities that directly influence clinical pathways and service design. When considering end users such as Ambulatory Surgical Centers, Hospitals, and Specialty Clinics, procedural volumes, perioperative capabilities, and multidisciplinary coordination requirements differ in ways that affect patient throughput and resource allocation; ambulatory settings emphasize efficiency and short-stay management, hospitals provide comprehensive perioperative and complex case management, and specialty clinics often concentrate subspecialized outpatient therapies and follow-up.

Examining cancer type distinctions between Adenocarcinoma and Squamous Cell Carcinoma highlights divergent etiologies, risk factor profiles, and therapeutic vulnerabilities; adenocarcinoma is frequently associated with gastroesophageal reflux and Barrett's esophagus and often presents opportunities for targeted therapy based on molecular markers, whereas squamous disease may be more prevalent in populations with distinct exposure risks and can respond differently to chemoradiation approaches. Disease stage segmentation across Stage I, Stage II, Stage III, and Stage IV illustrates how early-stage management prioritizes curative-intent modalities including surgical and endoscopic resection, while advanced stages rely increasingly on systemic therapies and integrated palliative strategies to preserve quality of life.

Treatment type stratification spans Chemotherapy, Immunotherapy, Radiotherapy, Surgery, and Targeted Therapy, with chemotherapy further subdivided into adjuvant, neoadjuvant, and palliative approaches that shape timing and sequencing decisions. Immunotherapeutic approaches include cancer vaccines and checkpoint inhibitors, each with specific biomarker dependencies and toxicity management considerations. Targeted therapies focus on EGFR inhibitors, HER2 inhibitors, and VEGF inhibitors, and their clinical integration depends on validated biomarker testing and multidisciplinary care planning. These layered segmentations underscore the importance of aligning diagnostic capabilities, clinical expertise, and reimbursement frameworks to optimize outcomes across distinct patient cohorts.

How regional system dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific influence access, diagnostic capacity, and therapeutic adoption in esophageal cancer

Regional dynamics shape clinical practice patterns, regulatory timelines, and access pathways in ways that meaningfully affect the adoption of diagnostics and therapeutics. In the Americas, concentrated centers of excellence coexist with broad regional variation in resource availability, producing a landscape where cutting-edge treatments are accessible in some urban hubs while peripheral systems emphasize efficient care delivery models and decentralized follow-up. Policy and reimbursement mechanisms in this region often drive rapid uptake of therapies with strong clinical benefit, but disparities in access remain a central concern.

In Europe, Middle East & Africa, heterogeneity across healthcare systems manifests in varying diagnostic capacity and bundled payment approaches, with some jurisdictions prioritizing centralized genomic testing and others relying on pragmatic clinical algorithms. Regulatory alignment across European markets facilitates cross-border collaboration on clinical trials but local reimbursement decisions continue to govern patient access. Capacity constraints and public health priorities in parts of the Middle East and Africa influence programmatic efforts to strengthen early detection and enable more standardized treatment pathways.

Asia-Pacific presents a mix of domestically driven innovation and strategic adoption of global therapeutic standards. High-volume clinical centers in several markets drive rapid accrual to trials and can accelerate real-world evidence generation, while other countries in the region expand infrastructure for molecular diagnostics and workforce training to address growing incidence. Across all regions, aligning clinical guidelines, diagnostic access, and value demonstration remains essential to improving outcomes and ensuring that emerging therapies reach appropriate patient groups.

Competitive and collaborative dynamics among pharmaceutical innovators, diagnostic developers, and device makers shaping therapeutic and diagnostic ecosystems in esophageal cancer

The competitive environment in esophageal cancer spans established pharmaceutical firms, emerging biotech companies, diagnostic platform providers, and specialized device manufacturers. Pharmaceutical developers are concentrating on combination regimens that pair targeted agents with immunotherapies and on refining biomarker-driven indications to identify patients most likely to benefit. Diagnostic companies are investing in assays that enable reliable detection of HER2, EGFR, and other actionable alterations from tissue and liquid biopsy specimens, while device manufacturers focus on scalable endoscopic and surgical technologies that reduce complication rates and support ambulatory care models.

Partnerships between therapeutic and diagnostic players are increasingly important to support companion diagnostics, enable streamlined trial enrollment, and facilitate post-market evidence collection. Smaller biotechnology firms often pursue innovative mechanisms of action and novel antigen targets, which larger firms may acquire or license to expand pipeline breadth. Health systems and specialty clinics are also evolving from purchasers into collaborators, participating in pragmatic trials and registries that help define real-world effectiveness and inform payer decisions. The interplay between clinical innovation, diagnostic validation, and commercial strategy defines the competitive contours of the field and will determine which solutions achieve sustainable clinical uptake.

Practical strategic recommendations for clinical, commercial, and supply chain leaders to accelerate equitable access and optimize therapeutic value in esophageal cancer

Industry leaders should prioritize investments that bridge diagnostic capability gaps and support biomarker-driven care pathways. Strengthening partnerships with pathology networks and investing in scalable molecular testing infrastructure will reduce time-to-treatment and improve patient selection for targeted and immunotherapeutic regimens. Manufacturers and payers should also collaborate on risk-sharing and value-based contracting models that align reimbursement with demonstrated outcomes, enabling broader access to high-cost therapies while incentivizing meaningful real-world evidence collection.

Operationally, healthcare providers should enhance multidisciplinary coordination across surgical, medical oncology, radiation oncology, and supportive care teams to optimize sequencing and manage toxicity. Supply chain resilience must be improved through diversified sourcing strategies and contingency planning to minimize disruptions related to trade policy volatility. Finally, stakeholder engagement with patient advocacy organizations and public health agencies can advance early detection initiatives and education campaigns, addressing disparities in presentation and enabling more patients to benefit from curative-intent interventions.

A rigorous mixed-methods research approach combining expert consultation, clinical evidence synthesis, and operational scenario analysis to inform strategic decision-making

This research integrates a multi-disciplinary evidence base combining peer-reviewed clinical literature, regulatory announcements, clinical guideline updates, and interviews with clinicians, diagnostics experts, and supply chain professionals. Primary research included structured expert consultations that explored therapeutic sequencing, diagnostic utility, and procurement dynamics, while secondary analysis synthesized published clinical trial outcomes, regulatory actions, and technology assessments to provide context for emerging trends.

Analytical approaches emphasized cross-validation of qualitative insights with documented clinical evidence and policy developments. The methodology prioritized transparency in data sources and assumptions, and applied scenario analysis to assess the operational implications of supply chain and regulatory shifts. Where applicable, the report highlights areas of consensus and identifies evidence gaps that warrant focused investigation or prospective real-world studies to strengthen decision-making.

A concise conclusion highlighting the imperative to integrate diagnostics, therapeutic innovation, and system-level resilience to improve outcomes in esophageal cancer

In summary, esophageal cancer management is at an inflection point in which diagnostic precision, therapeutic innovation, and system-level adaptability will determine whether clinical advances translate into improved patient outcomes at scale. Molecular profiling and the expansion of targeted and immune-based therapies offer tangible opportunities to personalize care, but realizing that potential requires investments in diagnostic infrastructure, multidisciplinary care coordination, and supply chain resilience.

Policymakers, providers, and industry stakeholders must work in concert to align incentives, address disparities in access, and commit to robust real-world evidence generation that substantiates therapeutic value. By focusing on scalable diagnostics, pragmatic treatment pathways, and collaborative contracting, stakeholders can accelerate the translation of scientific progress into meaningful clinical benefit for people living with esophageal cancer.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Esophageal Cancer Market, by Treatment Type

  • 8.1. Chemotherapy
    • 8.1.1. Adjuvant Therapy
    • 8.1.2. Neoadjuvant Therapy
    • 8.1.3. Palliative Therapy
  • 8.2. Immunotherapy
    • 8.2.1. Cancer Vaccines
    • 8.2.2. Checkpoint Inhibitors
  • 8.3. Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Her2 Inhibitors
    • 8.5.3. Vegf Inhibitors

9. Esophageal Cancer Market, by Cancer Type

  • 9.1. Adenocarcinoma
  • 9.2. Squamous Cell Carcinoma

10. Esophageal Cancer Market, by Disease Stage

  • 10.1. Stage I
  • 10.2. Stage Ii
  • 10.3. Stage Iii
  • 10.4. Stage Iv

11. Esophageal Cancer Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. Esophageal Cancer Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Esophageal Cancer Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Esophageal Cancer Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Esophageal Cancer Market

16. China Esophageal Cancer Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. AbbVie Inc.
  • 17.7. Amgen Inc.
  • 17.8. Astellas Pharma Inc.
  • 17.9. AstraZeneca plc
  • 17.10. Aurobindo Pharma Limited
  • 17.11. Bausch Health Companies Inc.
  • 17.12. Bayer AG
  • 17.13. Boehringer Ingelheim GmbH
  • 17.14. Bristol-Myers Squibb Company
  • 17.15. Cipla Inc.
  • 17.16. Eli Lilly and Company
  • 17.17. F. Hoffmann-La Roche Ltd
  • 17.18. GlaxoSmithKline Plc
  • 17.19. Hikma Pharmaceuticals PLC
  • 17.20. Jiangsu Hengrui Medicine Co., Ltd
  • 17.21. Johnson & Johnson Private Limited
  • 17.22. LEO Pharma A/S
  • 17.23. Merck & Co., Inc.
  • 17.24. Novartis AG
  • 17.25. Otsuka Pharmaceutical Co., Ltd.
  • 17.26. Pfizer Inc
  • 17.27. Sanofi S.A.
  • 17.28. Sun Pharmaceutical Industries Ltd.
  • 17.29. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ESOPHAGEAL CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ESOPHAGEAL CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADJUVANT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY NEOADJUVANT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY PALLIATIVE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HER2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY STAGE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. GCC ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. GCC ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 156. GCC ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. G7 ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 177. G7 ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NATO ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. NATO ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. NATO ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. NATO ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ESOPHAGEAL CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA ESOPHAGEAL CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY DISEASE STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA ESOPHAGEAL CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)